Nabriva Therapeutics (NBRV) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock NBRV vs. CYBN, LYEL, TIL, CRDF, LFVN, RAPT, DERM, ACRS, SLS, and PBYIShould you be buying Nabriva Therapeutics stock or one of its competitors? The main competitors of Nabriva Therapeutics include Cybin (CYBN), Lyell Immunopharma (LYEL), Instil Bio (TIL), Cardiff Oncology (CRDF), Lifevantage (LFVN), Rapt Therapeutics (RAPT), Journey Medical (DERM), Aclaris Therapeutics (ACRS), SELLAS Life Sciences Group (SLS), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical products" industry. Nabriva Therapeutics vs. Its Competitors Cybin Lyell Immunopharma Instil Bio Cardiff Oncology Lifevantage Rapt Therapeutics Journey Medical Aclaris Therapeutics SELLAS Life Sciences Group Puma Biotechnology Cybin (NYSE:CYBN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations. Does the media refer more to CYBN or NBRV? In the previous week, Cybin had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Cybin and 0 mentions for Nabriva Therapeutics. Cybin's average media sentiment score of 1.84 beat Nabriva Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the media. Company Overall Sentiment Cybin Very Positive Nabriva Therapeutics Neutral Is CYBN or NBRV more profitable? Cybin has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Cybin's return on equity of -37.58% beat Nabriva Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Nabriva Therapeutics -148.11%-365.53%-135.81% Do analysts recommend CYBN or NBRV? Cybin currently has a consensus target price of $85.00, suggesting a potential upside of 1,040.94%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Nabriva Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in CYBN or NBRV? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better earnings & valuation, CYBN or NBRV? Nabriva Therapeutics has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$3.88-1.92Nabriva Therapeutics$35.59M0.00-$57.19M-$19.20N/A Which has more volatility and risk, CYBN or NBRV? Cybin has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. SummaryCybin beats Nabriva Therapeutics on 12 of the 16 factors compared between the two stocks. Get Nabriva Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBRV vs. The Competition Export to ExcelMetricNabriva TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.46M$857.25M$5.51B$9.72BDividend YieldN/A4.84%4.60%4.12%P/E Ratio0.001.1630.0324.75Price / SalesN/A26.66450.3797.61Price / CashN/A19.5636.7758.47Price / BookN/A6.548.185.59Net Income-$57.19M-$4.07M$3.26B$265.99M Nabriva Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070CYBNCybin2.8401 of 5 stars$7.55-1.8%$85.00+1,026.6%N/A$178.22MN/A-1.7250LYELLyell Immunopharma3.315 of 5 stars$11.60+2.0%$15.00+29.4%-64.1%$177.95M$60K-0.46270Gap UpTILInstil Bio2.1537 of 5 stars$26.78+8.2%$119.00+344.4%+159.2%$177.02MN/A-2.25410Upcoming EarningsCRDFCardiff Oncology1.7327 of 5 stars$2.57+2.2%$11.70+356.1%+0.4%$171.32M$680K-2.9620News CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionLFVNLifevantage4.0659 of 5 stars$13.40+0.8%$30.50+127.6%+69.6%$168.59M$200.16M19.41260RAPTRapt Therapeutics4.2892 of 5 stars$10.10-6.1%$20.57+103.7%-46.0%$167.82M$1.53M-0.5380News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionDERMJourney Medical1.7066 of 5 stars$7.19+0.6%$9.50+32.2%+52.0%$167.67M$56.13M-18.4590News CoverageUpcoming EarningsACRSAclaris Therapeutics1.918 of 5 stars$1.56-0.3%$8.71+460.4%+40.5%$167.29M$18.72M-1.11100News CoverageEarnings ReportSLSSELLAS Life Sciences Group2.2862 of 5 stars$1.62+1.6%$7.00+333.4%+30.6%$160.15M$1M-4.2210News CoverageUpcoming EarningsPBYIPuma Biotechnology4.0279 of 5 stars$3.23+1.5%$7.00+116.9%-1.9%$160.11M$230.50M4.19200News CoverageAnalyst DowngradeGap Down Related Companies and Tools Related Companies CYBN Alternatives LYEL Alternatives TIL Alternatives CRDF Alternatives LFVN Alternatives RAPT Alternatives DERM Alternatives ACRS Alternatives SLS Alternatives PBYI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBRV) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nabriva Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBRV Stock Alerts